603259 药明康德
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入12,435,77728.81%45,456,16639,241,43140,340,80739,354,778
减:营业总成本7,433,44610.75%29,148,15527,342,26828,708,59129,800,811
    其中:营业成本6,167,82310.64%23,801,43522,964,51523,728,80024,677,217
               财务费用14,682-79.50%398,191(786,684)(338,119)(247,968)
               资产减值损失(41,177)-73.64%(541,556)(1,236,258)(156,509)(175,951)
公允价值变动收益459,261-1,099.73%(137,098)186,958(37,809)770,079
投资收益164,837-89.28%8,588,017604,162233,849187,949
    其中:对联营企业和合营企业的投资收益138,966117.13%452,582245,065(67,560)(46,271)
营业利润5,614,93730.80%23,930,08411,580,17511,872,28610,652,249
利润总额5,607,28031.01%23,906,15111,539,81211,831,99110,618,476
减:所得税费用936,76665.97%4,573,0851,972,0722,131,7311,715,866
净利润4,670,51425.70%19,333,0669,567,7409,700,2608,902,611
减:非控股权益18,996-56.34%182,483117,43193,51188,898
股东净利润4,651,51826.68%19,150,5829,450,3089,606,7498,813,713

市场价值指针
每股收益 (元) *1.59023.26%6.7003.2803.2703.010
每股派息 (元) *----2.2790.9820.9900.893
每股净资产 (元) *----26.71520.30218.57015.737
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容